#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-8	Abnormal	_
1-2	9-15	neural	_
1-3	16-25	hierarchy	_
1-4	26-28	in	_
1-5	29-39	processing	_
1-6	40-42	of	_
1-7	43-49	verbal	_
1-8	50-61	information	_
1-9	62-64	in	_
1-10	65-73	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-11	74-78	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	79-92	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-13	93-101	Previous	_
1-14	102-110	research	_
1-15	111-120	indicates	_
1-16	121-129	abnormal	_
1-17	130-143	comprehension	_
1-18	144-146	of	_
1-19	147-153	verbal	_
1-20	154-165	information	_
1-21	166-168	in	_
1-22	169-177	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-23	178-182	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-24	183-196	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-25	197-198	.	_

2-1	199-202	Yet	_
2-2	203-206	the	_
2-3	207-213	neural	_
2-4	214-223	mechanism	_
2-5	224-234	underlying	_
2-6	235-238	the	_
2-7	239-248	breakdown	_
2-8	249-251	of	_
2-9	252-258	verbal	_
2-10	259-270	information	_
2-11	271-281	processing	_
2-12	282-284	in	_
2-13	285-298	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-14	299-301	is	_
2-15	302-308	poorly	_
2-16	309-319	understood	_
2-17	320-321	.	_

3-1	322-329	Imaging	_
3-2	330-337	studies	_
3-3	338-340	in	_
3-4	341-348	healthy	_
3-5	349-360	populations	_
3-6	361-365	have	_
3-7	366-371	shown	_
3-8	372-373	a	_
3-9	374-381	network	_
3-10	382-384	of	_
3-11	385-390	brain	_
3-12	391-396	areas	_
3-13	397-405	involved	_
3-14	406-408	in	_
3-15	409-421	hierarchical	_
3-16	422-432	processing	_
3-17	433-435	of	_
3-18	436-442	verbal	_
3-19	443-454	information	_
3-20	455-459	over	_
3-21	460-464	time	_
3-22	465-466	.	_

4-1	467-471	Here	_
4-2	472-473	,	_
4-3	474-476	we	_
4-4	477-487	identified	_
4-5	488-496	critical	_
4-6	497-504	aspects	_
4-7	505-507	of	_
4-8	508-512	this	_
4-9	513-522	hierarchy	_
4-10	523-524	,	_
4-11	525-534	examining	_
4-12	535-543	patients	_
4-13	544-548	with	_
4-14	549-562	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-15	563-564	.	_

5-1	565-570	Using	_
5-2	571-581	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-3	582-590	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-4	591-600	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-5	601-608	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-6	609-610	,	_
5-7	611-613	we	_
5-8	614-622	examined	_
5-9	623-630	various	_
5-10	631-637	levels	_
5-11	638-640	of	_
5-12	641-652	information	_
5-13	653-666	comprehension	_
5-14	667-675	elicited	_
5-15	676-678	by	_
5-16	679-688	naturally	_
5-17	689-698	presented	_
5-18	699-705	verbal	_
5-19	706-713	stimuli	_
5-20	714-715	;	_
5-21	716-720	from	_
5-22	721-722	a	_
5-23	723-726	set	_
5-24	727-729	of	_
5-25	730-738	randomly	_
5-26	739-747	shuffled	_
5-27	748-753	words	_
5-28	754-756	to	_
5-29	757-759	an	_
5-30	760-766	intact	_
5-31	767-772	story	_
5-32	773-774	.	_

6-1	775-787	Specifically	_
6-2	788-789	,	_
6-3	790-798	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-4	799-803	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-5	804-809	first	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-6	810-817	episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-7	818-831	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-8	832-833	(	_
6-9	834-835	N	_
6-10	836-837	=	_
6-11	838-840	15	_
6-12	841-842	)	_
6-13	843-844	,	_
6-14	845-850	their	_
6-15	851-866	non-manifesting	_
6-16	867-875	siblings	_
6-17	876-877	(	_
6-18	878-879	N	_
6-19	880-881	=	_
6-20	882-884	14	_
6-21	885-886	)	_
6-22	887-890	and	_
6-23	891-898	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-24	899-907	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-25	908-909	(	_
6-26	910-911	N	_
6-27	912-913	=	_
6-28	914-916	15	_
6-29	917-918	)	_
6-30	919-927	listened	_
6-31	928-930	to	_
6-32	931-932	a	_
6-33	933-941	narrated	_
6-34	942-947	story	_
6-35	948-951	and	_
6-36	952-960	randomly	_
6-37	961-970	scrambled	_
6-38	971-979	versions	_
6-39	980-982	of	_
6-40	983-985	it	_
6-41	986-987	.	_

7-1	988-990	To	_
7-2	991-999	quantify	_
7-3	1000-1003	the	_
7-4	1004-1010	degree	_
7-5	1011-1013	of	_
7-6	1014-1027	dissimilarity	_
7-7	1028-1035	between	_
7-8	1036-1039	the	_
7-9	1040-1046	groups	_
7-10	1047-1048	,	_
7-11	1049-1051	we	_
7-12	1052-1059	adopted	_
7-13	1060-1062	an	_
7-14	1063-1076	inter-subject	_
7-15	1077-1088	correlation	_
7-16	1089-1090	(	_
7-17	1091-1099	inter-SC	_
7-18	1100-1101	)	_
7-19	1102-1110	approach	_
7-20	1111-1112	,	_
7-21	1113-1118	which	_
7-22	1119-1128	estimates	_
7-23	1129-1140	differences	_
7-24	1141-1143	in	_
7-25	1144-1159	synchronization	_
7-26	1160-1162	of	_
7-27	1163-1169	neural	_
7-28	1170-1179	responses	_
7-29	1180-1186	within	_
7-30	1187-1190	and	_
7-31	1191-1198	between	_
7-32	1199-1205	groups	_
7-33	1206-1207	.	_

8-1	1208-1211	The	_
8-2	1212-1220	temporal	_
8-3	1221-1231	topography	_
8-4	1232-1237	found	_
8-5	1238-1240	in	_
8-6	1241-1248	healthy	_
8-7	1249-1252	and	_
8-8	1253-1261	siblings	_
8-9	1262-1268	groups	_
8-10	1269-1273	were	_
8-11	1274-1284	consistent	_
8-12	1285-1289	with	_
8-13	1290-1293	our	_
8-14	1294-1302	previous	_
8-15	1303-1311	findings	_
8-16	1312-1313	–	_
8-17	1314-1318	high	_
8-18	1319-1334	synchronization	_
8-19	1335-1337	in	_
8-20	1338-1347	responses	_
8-21	1348-1352	from	_
8-22	1353-1358	early	_
8-23	1359-1366	sensory	_
8-24	1367-1373	toward	_
8-25	1374-1378	high	_
8-26	1379-1384	order	_
8-27	1385-1395	perceptual	_
8-28	1396-1399	and	_
8-29	1400-1409	cognitive	_
8-30	1410-1415	areas	_
8-31	1416-1417	.	_

9-1	1418-1420	In	_
9-2	1421-1429	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-3	1430-1434	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-4	1435-1448	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-5	1449-1450	,	_
9-6	1451-1458	stimuli	_
9-7	1459-1463	with	_
9-8	1464-1469	short	_
9-9	1470-1473	and	_
9-10	1474-1486	intermediate	_
9-11	1487-1495	temporal	_
9-12	1496-1502	scales	_
9-13	1503-1509	evoked	_
9-14	1510-1511	a	_
9-15	1512-1519	typical	_
9-16	1520-1527	pattern	_
9-17	1528-1530	of	_
9-18	1531-1539	reliable	_
9-19	1540-1549	responses	_
9-20	1550-1551	,	_
9-21	1552-1559	whereas	_
9-22	1560-1565	story	_
9-23	1566-1575	condition	_
9-24	1576-1577	(	_
9-25	1578-1582	long	_
9-26	1583-1591	temporal	_
9-27	1592-1597	scale	_
9-28	1598-1599	)	_
9-29	1600-1608	revealed	_
9-30	1609-1615	robust	_
9-31	1616-1619	and	_
9-32	1620-1630	widespread	_
9-33	1631-1641	disruption	_
9-34	1642-1644	of	_
9-35	1645-1648	the	_
9-36	1649-1658	inter-SCs	_
9-37	1659-1660	.	_

10-1	1661-1663	In	_
10-2	1664-1672	addition	_
10-3	1673-1674	,	_
10-4	1675-1678	the	_
10-5	1679-1683	more	_
10-6	1684-1691	similar	_
10-7	1692-1695	the	_
10-8	1696-1702	neural	_
10-9	1703-1711	activity	_
10-10	1712-1714	of	_
10-11	1715-1723	patients	_
10-12	1724-1728	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-13	1729-1742	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-14	1743-1746	was	_
10-15	1747-1749	to	_
10-16	1750-1753	the	_
10-17	1754-1761	average	_
10-18	1762-1770	response	_
10-19	1771-1773	in	_
10-20	1774-1777	the	_
10-21	1778-1785	healthy	_
10-22	1786-1791	group	_
10-23	1792-1793	,	_
10-24	1794-1797	the	_
10-25	1798-1802	less	_
10-26	1803-1809	severe	_
10-27	1810-1813	the	_
10-28	1814-1822	positive	_
10-29	1823-1831	symptoms	_
10-30	1832-1834	of	_
10-31	1835-1838	the	_
10-32	1839-1847	patients	_
10-33	1848-1849	.	_

11-1	1850-1853	Our	_
11-2	1854-1862	findings	_
11-3	1863-1870	suggest	_
11-4	1871-1875	that	_
11-5	1876-1888	system-level	_
11-6	1889-1895	neural	_
11-7	1896-1906	indication	_
11-8	1907-1909	of	_
11-9	1910-1918	abnormal	_
11-10	1919-1925	verbal	_
11-11	1926-1937	information	_
11-12	1938-1948	processing	_
11-13	1949-1951	in	_
11-14	1952-1965	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-15	1966-1974	reflects	_
11-16	1975-1982	disease	_
11-17	1983-1997	manifestations	_
11-18	1998-1999	.	_

12-1	2000-2010	Highlights	_
12-2	2011-2019	Critical	_
12-3	2020-2027	aspects	_
12-4	2028-2030	in	_
12-5	2031-2039	semantic	_
12-6	2040-2051	information	_
12-7	2052-2062	processing	_
12-8	2063-2065	in	_
12-9	2066-2074	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-10	2075-2079	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-11	2080-2093	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-12	2094-2095	,	_
12-13	2096-2101	their	_
12-14	2102-2117	non-manifesting	_
12-15	2118-2126	siblings	_
12-16	2127-2130	and	_
12-17	2131-2138	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-18	2139-2147	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-19	2148-2152	High	_
12-20	2153-2168	synchronization	_
12-21	2169-2171	in	_
12-22	2172-2181	responses	_
12-23	2182-2184	in	_
12-24	2185-2190	early	_
12-25	2191-2198	sensory	_
12-26	2199-2204	areas	_
12-27	2205-2207	in	_
12-28	2208-2211	all	_
12-29	2212-2218	groups	_
12-30	2219-2225	Robust	_
12-31	2226-2236	disruption	_
12-32	2237-2239	of	_
12-33	2240-2243	the	_
12-34	2244-2253	responses	_
12-35	2254-2256	in	_
12-36	2257-2261	high	_
12-37	2262-2267	order	_
12-38	2268-2278	perceptual	_
12-39	2279-2282	and	_
12-40	2283-2292	cognitive	_
12-41	2293-2298	areas	_
12-42	2299-2301	in	_
12-43	2302-2310	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-44	2311-2315	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-45	2316-2329	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-46	2330-2339	Materials	_
12-47	2340-2343	and	_
12-48	2344-2351	methods	_
12-49	2352-2364	Participants	_
12-50	2365-2370	Three	_
12-51	2371-2377	groups	_
12-52	2378-2382	were	_
12-53	2383-2392	evaluated	_
12-54	2393-2394	:	_
12-55	2395-2397	16	_
12-56	2398-2408	inpatients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-57	2409-2413	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-58	2414-2419	first	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-59	2420-2427	episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-60	2428-2441	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-61	2442-2451	recruited	_
12-62	2452-2456	from	_
12-63	2457-2460	the	_
12-64	2461-2466	MAZOR	_
12-65	2467-2473	Mental	_
12-66	2474-2480	Health	_
12-67	2481-2487	Center	_
12-68	2488-2489	(	_
12-69	2490-2492	3F	_
12-70	2493-2494	;	_
12-71	2495-2500	19–46	_
12-72	2501-2506	years	_
12-73	2507-2508	,	_
12-74	2509-2513	mean	_
12-75	2514-2517	age	_
12-76	2518-2520	27	_
12-77	2521-2522	;	_
12-78	2523-2524	1	_
12-79	2525-2533	excluded	_
12-80	2534-2535	(	_
12-81	2536-2539	see	_
12-82	2540-2553	Preprocessing	_
12-83	2554-2561	section	_
12-84	2562-2567	below	_
12-85	2568-2569	)	_
12-86	2570-2571	)	_
12-87	2572-2573	;	_
12-88	2574-2576	15	_
12-89	2577-2592	non-manifesting	_
12-90	2593-2601	siblings	_
12-91	2602-2604	of	_
12-92	2605-2608	the	_
12-93	2609-2617	patients	_
12-94	2618-2619	(	_
12-95	2620-2622	5F	_
12-96	2623-2624	;	_
12-97	2625-2630	19–37	_
12-98	2631-2636	years	_
12-99	2637-2638	,	_
12-100	2639-2643	mean	_
12-101	2644-2647	age	_
12-102	2648-2650	25	_
12-103	2651-2652	;	_
12-104	2653-2654	1	_
12-105	2655-2663	excluded	_
12-106	2664-2665	)	_
12-107	2666-2667	;	_
12-108	2668-2670	32	_
12-109	2671-2678	healthy	_
12-110	2679-2691	participants	_
12-111	2692-2693	(	_
12-112	2694-2696	15	_
12-113	2697-2699	in	_
12-114	2700-2703	the	_
12-115	2704-2708	main	_
12-116	2709-2714	study	_
12-117	2715-2716	:	_
12-118	2717-2719	5F	_
12-119	2720-2721	;	_
12-120	2722-2727	22–32	_
12-121	2728-2733	years	_
12-122	2734-2735	,	_
12-123	2736-2740	mean	_
12-124	2741-2744	age	_
12-125	2745-2747	26	_
12-126	2748-2749	;	_
12-127	2750-2752	12	_
12-128	2753-2763	additional	_
12-129	2764-2776	participants	_
12-130	2777-2778	(	_
12-131	2779-2781	9F	_
12-132	2782-2783	;	_
12-133	2784-2789	22–32	_
12-134	2790-2795	years	_
12-135	2796-2797	,	_
12-136	2798-2802	mean	_
12-137	2803-2806	age	_
12-138	2807-2809	26	_
12-139	2810-2811	)	_
12-140	2812-2816	were	_
12-141	2817-2821	used	_
12-142	2822-2824	in	_
12-143	2825-2828	the	_
12-144	2829-2832	ROI	_
12-145	2833-2842	selection	_
12-146	2843-2844	,	_
12-147	2845-2846	5	_
12-148	2847-2855	excluded	_
12-149	2856-2857	)	_
12-150	2858-2859	.	_

13-1	2860-2877	Socio-demographic	_
13-2	2878-2893	characteristics	_
13-3	2894-2896	of	_
13-4	2897-2909	participants	_
13-5	2910-2913	are	_
13-6	2914-2923	presented	_
13-7	2924-2926	in	_
13-8	2927-2932	Table	_
13-9	2933-2935	1A	_
13-10	2936-2937	.	_

14-1	2938-2946	Patients	_
14-2	2947-2951	were	_
14-3	2952-2961	diagnosed	_
14-4	2962-2964	by	_
14-5	2965-2971	senior	_
14-6	2972-2985	psychiatrists	_
14-7	2986-2991	while	_
14-8	2992-3004	hospitalized	_
14-9	3005-3006	,	_
14-10	3007-3012	based	_
14-11	3013-3015	on	_
14-12	3016-3019	the	_
14-13	3020-3030	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-14	3031-3039	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-15	3040-3049	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-16	3050-3053	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-17	3054-3060	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-18	3061-3067	Axis-I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-19	3068-3077	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-20	3078-3079	,	_
14-21	3080-3087	Patient	_
14-22	3088-3095	Edition	_
14-23	3096-3097	(	_
14-24	3098-3106	SCID-I/P	_
14-25	3107-3108	,	_
14-26	3109-3110	)	_
14-27	3111-3112	.	_

15-1	3113-3121	Severity	_
15-2	3122-3124	of	_
15-3	3125-3138	schizophrenia	_
15-4	3139-3147	symptoms	_
15-5	3148-3151	was	_
15-6	3152-3160	assessed	_
15-7	3161-3165	with	_
15-8	3166-3169	the	_
15-9	3170-3178	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
15-10	3179-3182	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
15-11	3183-3191	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
15-12	3192-3200	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
15-13	3201-3206	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
15-14	3207-3208	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
15-15	3209-3214	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
15-16	3215-3216	,	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
15-17	3217-3218	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
15-18	3219-3220	.	_

16-1	3221-3234	Pharmacologic	_
16-2	3235-3245	management	_
16-3	3246-3255	including	_
16-4	3256-3267	therapeutic	_
16-5	3268-3273	doses	_
16-6	3274-3276	of	_
16-7	3277-3293	first-generation	_
16-8	3294-3297	and	_
16-9	3298-3315	second-generation	_
16-10	3316-3330	antipsychotics	_
16-11	3331-3335	used	_
16-12	3336-3339	for	_
16-13	3340-3343	the	_
16-14	3344-3353	treatment	_
16-15	3354-3357	and	_
16-16	3358-3363	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
16-17	3364-3370	values	_
16-18	3371-3374	are	_
16-19	3375-3380	shown	_
16-20	3381-3383	in	_
16-21	3384-3389	Table	_
16-22	3390-3392	1B	_
16-23	3393-3396	and	_
16-24	3397-3402	Table	_
16-25	3403-3405	1C	_
16-26	3406-3407	,	_
16-27	3408-3420	respectively	_
16-28	3421-3422	(	_
16-29	3423-3426	for	_
16-30	3427-3430	the	_
16-31	3431-3441	individual	_
16-32	3442-3449	details	_
16-33	3450-3453	see	_
16-34	3454-3467	Supplementary	_
16-35	3468-3473	Table	_
16-36	3474-3475	1	_
16-37	3476-3477	)	_
16-38	3478-3479	.	_

17-1	3480-3483	The	_
17-2	3484-3485	p	_
17-3	3486-3492	values	_
17-4	3493-3496	for	_
17-5	3497-3508	statistical	_
17-6	3509-3514	tests	_
17-7	3515-3524	comparing	_
17-8	3525-3531	gender	_
17-9	3532-3533	,	_
17-10	3534-3537	age	_
17-11	3538-3539	,	_
17-12	3540-3552	bilingualism	_
17-13	3553-3556	and	_
17-14	3557-3562	years	_
17-15	3563-3565	of	_
17-16	3566-3575	education	_
17-17	3576-3579	are	_
17-18	3580-3585	shown	_
17-19	3586-3588	in	_
17-20	3589-3594	Table	_
17-21	3595-3597	1D	_
17-22	3598-3599	.	_

18-1	3600-3603	The	_
18-2	3604-3610	binary	_
18-3	3611-3617	values	_
18-4	3618-3619	(	_
18-5	3620-3626	gender	_
18-6	3627-3630	and	_
18-7	3631-3643	bilingualism	_
18-8	3644-3645	)	_
18-9	3646-3650	were	_
18-10	3651-3657	tested	_
18-11	3658-3663	using	_
18-12	3664-3667	the	_
18-13	3668-3676	binomial	_
18-14	3677-3682	exact	_
18-15	3683-3687	test	_
18-16	3688-3689	,	_
18-17	3690-3697	whereas	_
18-18	3698-3701	age	_
18-19	3702-3705	and	_
18-20	3706-3711	years	_
18-21	3712-3714	of	_
18-22	3715-3724	education	_
18-23	3725-3729	were	_
18-24	3730-3738	compared	_
18-25	3739-3744	using	_
18-26	3745-3748	the	_
18-27	3749-3768	Kolmogorov-Smirnoff	_
18-28	3769-3773	test	_
18-29	3774-3779	since	_
18-30	3780-3786	within	_
18-31	3787-3792	group	_
18-32	3793-3806	distributions	_
18-33	3807-3810	for	_
18-34	3811-3815	some	_
18-35	3816-3826	parameters	_
18-36	3827-3828	(	_
18-37	3829-3833	e.g.	_
18-38	3834-3835	,	_
18-39	3836-3839	age	_
18-40	3840-3841	)	_
18-41	3842-3846	were	_
18-42	3847-3850	not	_
18-43	3851-3857	normal	_
18-44	3858-3859	.	_

19-1	3860-3868	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-2	3869-3873	with	_
19-3	3874-3883	affective	_
19-4	3884-3887	and	_
19-5	3888-3895	organic	_
19-6	3896-3902	mental	_
19-7	3903-3912	disorders	_
19-8	3913-3914	(	_
19-9	3915-3920	other	_
19-10	3921-3925	than	_
19-11	3926-3939	schizophrenia	_
19-12	3940-3941	)	_
19-13	3942-3943	,	_
19-14	3944-3949	drug-	_
19-15	3950-3952	or	_
19-16	3953-3968	alcohol-induced	_
19-17	3969-3978	psychoses	_
19-18	3979-3983	were	_
19-19	3984-3987	not	_
19-20	3988-3996	included	_
19-21	3997-3998	.	_

20-1	3999-4006	Medical	_
20-2	4007-4010	and	_
20-3	4011-4023	neurological	_
20-4	4024-4033	illnesses	_
20-5	4034-4038	were	_
20-6	4039-4044	ruled	_
20-7	4045-4048	out	_
20-8	4049-4051	by	_
20-9	4052-4059	reports	_
20-10	4060-4064	from	_
20-11	4065-4073	patients	_
20-12	4074-4075	'	_
20-13	4076-4084	treating	_
20-14	4085-4095	physicians	_
20-15	4096-4099	and	_
20-16	4100-4107	medical	_
20-17	4108-4115	records	_
20-18	4116-4117	.	_

21-1	4118-4125	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
21-2	4126-4138	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
21-3	4139-4143	were	_
21-4	4144-4153	recruited	_
21-5	4154-4158	from	_
21-6	4159-4162	the	_
21-7	4163-4168	local	_
21-8	4169-4178	community	_
21-9	4179-4180	,	_
21-10	4181-4184	and	_
21-11	4185-4193	reported	_
21-12	4194-4196	no	_
21-13	4197-4205	previous	_
21-14	4206-4218	neurological	_
21-15	4219-4221	or	_
21-16	4222-4233	psychiatric	_
21-17	4234-4242	symptoms	_
21-18	4243-4245	or	_
21-19	4246-4253	hearing	_
21-20	4254-4265	impairments	_
21-21	4266-4267	.	_

22-1	4268-4271	All	_
22-2	4272-4284	participants	_
22-3	4285-4289	were	_
22-4	4290-4296	Hebrew	_
22-5	4297-4305	speakers	_
22-6	4306-4310	with	_
22-7	4311-4319	adequate	_
22-8	4320-4328	language	_
22-9	4329-4342	comprehension	_
22-10	4343-4344	.	_

23-1	4345-4355	Procedures	_
23-2	4356-4360	were	_
23-3	4361-4369	approved	_
23-4	4370-4372	by	_
23-5	4373-4376	the	_
23-6	4377-4385	Helsinki	_
23-7	4386-4395	Committee	_
23-8	4396-4398	on	_
23-9	4399-4409	Activities	_
23-10	4410-4419	Involving	_
23-11	4420-4425	Human	_
23-12	4426-4434	Subjects	_
23-13	4435-4437	in	_
23-14	4438-4441	Tel	_
23-15	4442-4446	Aviv	_
23-16	4447-4455	Sourasky	_
23-17	4456-4463	Medical	_
23-18	4464-4470	Center	_
23-19	4471-4472	(	_
23-20	4473-4478	TASMC	_
23-21	4479-4480	)	_
23-22	4481-4484	and	_
23-23	4485-4490	MAZOR	_
23-24	4491-4497	Mental	_
23-25	4498-4504	Health	_
23-26	4505-4511	Center	_
23-27	4512-4513	;	_
23-28	4514-4517	all	_
23-29	4518-4530	participants	_
23-30	4531-4539	provided	_
23-31	4540-4547	written	_
23-32	4548-4556	informed	_
23-33	4557-4564	consent	_
23-34	4565-4567	to	_
23-35	4568-4579	participate	_
23-36	4580-4582	in	_
23-37	4583-4586	the	_
23-38	4587-4592	study	_
23-39	4593-4594	.	_

24-1	4595-4599	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-2	4600-4604	data	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-3	4605-4616	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-4	4617-4621	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
24-5	4622-4630	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
24-6	4631-4634	was	_
24-7	4635-4644	performed	_
24-8	4645-4649	with	_
24-9	4650-4651	a	_
24-10	4652-4655	3.0	http://maven.renci.org/NeuroBridge/neurobridge#2Level
24-11	4656-4657	T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
24-12	4658-4663	Signa	http://maven.renci.org/NeuroBridge/neurobridge#2Level
24-13	4664-4670	Excite	http://maven.renci.org/NeuroBridge/neurobridge#2Level
24-14	4671-4675	echo	http://maven.renci.org/NeuroBridge/neurobridge#2Level
24-15	4676-4681	speed	http://maven.renci.org/NeuroBridge/neurobridge#2Level
24-16	4682-4689	scanner	http://maven.renci.org/NeuroBridge/neurobridge#2Level
24-17	4690-4691	(	_
24-18	4692-4699	General	_
24-19	4700-4708	Electric	_
24-20	4709-4716	Medical	_
24-21	4717-4724	Systems	_
24-22	4725-4726	)	_
24-23	4727-4728	,	_
24-24	4729-4734	using	_
24-25	4735-4737	an	_
24-26	4738-4747	8-channel	_
24-27	4748-4752	head	_
24-28	4753-4757	coil	_
24-29	4758-4759	,	_
24-30	4760-4762	at	_
24-31	4763-4768	TASMC	_
24-32	4769-4770	.	_

25-1	4771-4781	Structural	_
25-2	4782-4787	scans	_
25-3	4788-4796	included	_
25-4	4797-4798	a	_
25-5	4799-4810	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-6	4811-4813	3D	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-7	4814-4819	axial	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-8	4820-4827	spoiled	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-9	4828-4836	gradient	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-10	4837-4841	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-11	4842-4843	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-12	4844-4848	SPGR	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-13	4849-4850	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-14	4851-4856	pulse	_
25-15	4857-4865	sequence	_
25-16	4866-4867	(	_
25-17	4868-4878	repetition	_
25-18	4879-4883	time	_
25-19	4884-4885	(	_
25-20	4886-4888	TR	_
25-21	4889-4890	)	_
25-22	4891-4896	/echo	_
25-23	4897-4901	time	_
25-24	4902-4903	(	_
25-25	4904-4906	TE	_
25-26	4907-4908	)	_
25-27	4909-4910	=	_
25-28	4911-4920	8.94/3.48	_
25-29	4921-4923	ms	_
25-30	4924-4925	,	_
25-31	4926-4931	slice	_
25-32	4932-4941	thickness	_
25-33	4942-4943	=	_
25-34	4944-4945	1	_
25-35	4946-4948	mm	_
25-36	4949-4950	,	_
25-37	4951-4955	flip	_
25-38	4956-4961	angle	_
25-39	4962-4963	=	_
25-40	4964-4967	13°	_
25-41	4968-4969	,	_
25-42	4970-4975	pixel	_
25-43	4976-4980	size	_
25-44	4981-4982	=	_
25-45	4983-4984	1	_
25-46	4985-4987	mm	_
25-47	4988-4989	,	_
25-48	4990-5003	field-of-view	_
25-49	5004-5005	(	_
25-50	5006-5009	FOV	_
25-51	5010-5011	)	_
25-52	5012-5013	=	_
25-53	5014-5017	256	_
25-54	5018-5019	×	_
25-55	5020-5023	256	_
25-56	5024-5026	mm	_
25-57	5027-5028	)	_
25-58	5029-5030	.	_

26-1	5031-5041	Functional	_
26-2	5042-5053	whole-brain	_
26-3	5054-5059	scans	_
26-4	5060-5064	were	_
26-5	5065-5074	performed	_
26-6	5075-5077	in	_
26-7	5078-5089	interleaved	_
26-8	5090-5095	order	_
26-9	5096-5100	with	_
26-10	5101-5102	a	_
26-11	5103-5105	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-12	5106-5107	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-13	5108-5117	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-14	5118-5126	gradient	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-15	5127-5131	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-16	5132-5138	planar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-17	5139-5146	imaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-18	5147-5152	pulse	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-19	5153-5161	sequence	_
26-20	5162-5163	(	_
26-21	5164-5169	TR/TE	_
26-22	5170-5171	=	_
26-23	5172-5179	3000/35	_
26-24	5180-5182	ms	_
26-25	5183-5184	,	_
26-26	5185-5189	flip	_
26-27	5190-5195	angle	_
26-28	5196-5197	=	_
26-29	5198-5201	90°	_
26-30	5202-5203	,	_
26-31	5204-5209	pixel	_
26-32	5210-5214	size	_
26-33	5215-5216	=	_
26-34	5217-5221	1.56	_
26-35	5222-5224	mm	_
26-36	5225-5226	,	_
26-37	5227-5230	FOV	_
26-38	5231-5232	=	_
26-39	5233-5236	200	_
26-40	5237-5238	×	_
26-41	5239-5242	200	_
26-42	5243-5245	mm	_
26-43	5246-5247	,	_
26-44	5248-5253	slice	_
26-45	5254-5263	thickness	_
26-46	5264-5265	=	_
26-47	5266-5267	3	_
26-48	5268-5270	mm	_
26-49	5271-5272	,	_
26-50	5273-5275	39	_
26-51	5276-5289	slices/volume	_
26-52	5290-5291	)	_
26-53	5292-5293	.	_

27-1	5294-5308	MRI-compatible	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-2	5309-5319	headphones	_
27-3	5320-5321	(	_
27-4	5322-5334	OPTOACTIVEtm	_
27-5	5335-5336	)	_
27-6	5337-5341	were	_
27-7	5342-5346	used	_
27-8	5347-5349	to	_
27-9	5350-5362	considerably	_
27-10	5363-5372	attenuate	_
27-11	5373-5376	the	_
27-12	5377-5384	scanner	_
27-13	5385-5390	noise	_
27-14	5391-5394	and	_
27-15	5395-5397	to	_
27-16	5398-5405	present	_
27-17	5406-5409	the	_
27-18	5410-5415	audio	_
27-19	5416-5423	stimuli	_
27-20	5424-5425	.	_

28-1	5426-5433	Stimuli	_
28-2	5434-5437	and	_
28-3	5438-5450	experimental	_
28-4	5451-5460	procedure	_
28-5	5461-5468	Stimuli	_
28-6	5469-5473	were	_
28-7	5474-5483	generated	_
28-8	5484-5488	from	_
28-9	5489-5491	an	_
28-10	5492-5497	8-min	_
28-11	5498-5506	narrated	_
28-12	5507-5512	story	_
28-13	5513-5517	told	_
28-14	5518-5520	in	_
28-15	5521-5527	Hebrew	_
28-16	5528-5530	by	_
28-17	5531-5532	a	_
28-18	5533-5545	professional	_
28-19	5546-5557	storyteller	_
28-20	5558-5559	.	_

29-1	5560-5572	Participants	_
29-2	5573-5581	listened	_
29-3	5582-5584	to	_
29-4	5585-5588	the	_
29-5	5589-5594	whole	_
29-6	5595-5600	story	_
29-7	5601-5602	(	_
29-8	5603-5610	forward	_
29-9	5611-5620	condition	_
29-10	5621-5622	)	_
29-11	5623-5624	,	_
29-12	5625-5627	as	_
29-13	5628-5632	well	_
29-14	5633-5635	as	_
29-15	5636-5638	to	_
29-16	5639-5646	stimuli	_
29-17	5647-5654	created	_
29-18	5655-5657	by	_
29-19	5658-5668	scrambling	_
29-20	5669-5671	of	_
29-21	5672-5675	the	_
29-22	5676-5684	language	_
29-23	5685-5695	structures	_
29-24	5696-5698	in	_
29-25	5699-5702	the	_
29-26	5703-5708	story	_
29-27	5709-5710	(	_
29-28	5711-5714	Fig	_
29-29	5715-5716	.	_

30-1	5717-5719	1A	_
30-2	5720-5721	)	_
30-3	5722-5723	.	_

31-1	5724-5736	Specifically	_
31-2	5737-5738	,	_
31-3	5739-5741	in	_
31-4	5742-5751	scrambled	_
31-5	5752-5762	conditions	_
31-6	5763-5764	,	_
31-7	5765-5768	the	_
31-8	5769-5772	end	_
31-9	5773-5779	points	_
31-10	5780-5782	of	_
31-11	5783-5787	each	_
31-12	5788-5792	word	_
31-13	5793-5796	and	_
31-14	5797-5805	sentence	_
31-15	5806-5810	were	_
31-16	5811-5818	defined	_
31-17	5819-5827	manually	_
31-18	5828-5831	and	_
31-19	5832-5841	scrambled	_
31-20	5842-5844	by	_
31-21	5845-5846	a	_
31-22	5847-5853	random	_
31-23	5854-5863	shuffling	_
31-24	5864-5866	of	_
31-25	5867-5870	the	_
31-26	5871-5876	order	_
31-27	5877-5879	of	_
31-28	5880-5883	the	_
31-29	5884-5892	segments	_
31-30	5893-5894	.	_

32-1	5895-5897	In	_
32-2	5898-5901	the	_
32-3	5902-5911	scrambled	_
32-4	5912-5917	words	_
32-5	5918-5919	,	_
32-6	5920-5923	two	_
32-7	5924-5929	short	_
32-8	5930-5935	words	_
32-9	5936-5940	were	_
32-10	5941-5947	joined	_
32-11	5948-5950	in	_
32-12	5951-5956	cases	_
32-13	5957-5962	where	_
32-14	5963-5965	we	_
32-15	5966-5971	could	_
32-16	5972-5975	not	_
32-17	5976-5984	separate	_
32-18	5985-5988	the	_
32-19	5989-5997	adjacent	_
32-20	5998-6003	words	_
32-21	6004-6005	.	_

33-1	6006-6008	In	_
33-2	6009-6012	the	_
33-3	6013-6022	scrambled	_
33-4	6023-6032	sentences	_
33-5	6033-6034	,	_
33-6	6035-6037	we	_
33-7	6038-6046	verified	_
33-8	6047-6051	that	_
33-9	6052-6055	two	_
33-10	6056-6067	consecutive	_
33-11	6068-6077	sentences	_
33-12	6078-6082	from	_
33-13	6083-6086	the	_
33-14	6087-6095	original	_
33-15	6096-6101	story	_
33-16	6102-6105	did	_
33-17	6106-6109	not	_
33-18	6110-6116	follow	_
33-19	6117-6121	each	_
33-20	6122-6127	other	_
33-21	6128-6129	.	_

34-1	6130-6135	Short	_
34-2	6136-6144	examples	_
34-3	6145-6147	of	_
34-4	6148-6151	the	_
34-5	6152-6162	conditions	_
34-6	6163-6166	are	_
34-7	6167-6175	provided	_
34-8	6176-6178	in	_
34-9	6179-6192	Supplementary	_
34-10	6193-6197	File	_
34-11	6198-6199	1	_
34-12	6200-6201	.	_

35-1	6202-6206	Each	_
35-2	6207-6216	scrambled	_
35-3	6217-6226	condition	_
35-4	6227-6233	served	_
35-5	6234-6236	to	_
35-6	6237-6244	isolate	_
35-7	6245-6248	the	_
35-8	6249-6259	contextual	_
35-9	6260-6271	information	_
35-10	6272-6281	available	_
35-11	6282-6285	for	_
35-12	6286-6299	comprehension	_
35-13	6300-6302	as	_
35-14	6303-6304	a	_
35-15	6305-6313	function	_
35-16	6314-6316	of	_
35-17	6317-6321	that	_
35-18	6322-6330	specific	_
35-19	6331-6339	language	_
35-20	6340-6349	structure	_
35-21	6350-6351	,	_
35-22	6352-6356	thus	_
35-23	6357-6365	yielding	_
35-24	6366-6369	the	_
35-25	6370-6375	three	_
35-26	6376-6385	different	_
35-27	6386-6390	time	_
35-28	6391-6397	scales	_
35-29	6398-6399	(	_
35-30	6400-6405	short	_
35-31	6406-6407	–	_
35-32	6408-6409	“	_
35-33	6410-6415	words	_
35-34	6416-6421	scram	_
35-35	6422-6423	”	_
35-36	6424-6425	,	_
35-37	6426-6438	intermediate	_
35-38	6439-6440	–	_
35-39	6441-6442	“	_
35-40	6443-6452	sentences	_
35-41	6453-6458	scram	_
35-42	6459-6460	”	_
35-43	6461-6464	and	_
35-44	6465-6469	long	_
35-45	6470-6471	–	_
35-46	6472-6477	story	_
35-47	6478-6479	)	_
35-48	6480-6483	for	_
35-49	6484-6495	information	_
35-50	6496-6506	processing	_
35-51	6507-6508	.	_

36-1	6509-6520	Importantly	_
36-2	6521-6522	,	_
36-3	6523-6527	each	_
36-4	6528-6537	scrambled	_
36-5	6538-6545	version	_
36-6	6546-6555	contained	_
36-7	6556-6563	exactly	_
36-8	6564-6567	the	_
36-9	6568-6572	same	_
36-10	6573-6584	information	_
36-11	6585-6586	,	_
36-12	6587-6591	only	_
36-13	6592-6594	at	_
36-14	6595-6596	a	_
36-15	6597-6606	different	_
36-16	6607-6612	level	_
36-17	6613-6615	of	_
36-18	6616-6624	language	_
36-19	6625-6629	time	_
36-20	6630-6635	scale	_
36-21	6636-6637	(	_
36-22	6638-6641	i.e	_
36-23	6642-6643	.	_

37-1	6644-6649	words	_
37-2	6650-6651	,	_
37-3	6652-6661	sentences	_
37-4	6662-6663	)	_
37-5	6664-6665	.	_

38-1	6666-6671	Short	_
38-2	6672-6680	stimulus	_
38-3	6681-6689	included	_
38-4	6690-6693	656	_
38-5	6694-6699	words	_
38-6	6700-6701	(	_
38-7	6702-6703	a	_
38-8	6704-6708	word	_
38-9	6709-6715	lasted	_
38-10	6716-6718	on	_
38-11	6719-6726	average	_
38-12	6727-6730	0.7	_
38-13	6731-6732	s	_
38-14	6733-6734	)	_
38-15	6735-6736	;	_
38-16	6737-6749	intermediate	_
38-17	6750-6758	stimulus	_
38-18	6759-6767	included	_
38-19	6768-6770	76	_
38-20	6771-6780	sentences	_
38-21	6781-6782	(	_
38-22	6783-6784	a	_
38-23	6785-6793	sentence	_
38-24	6794-6800	lasted	_
38-25	6801-6803	on	_
38-26	6804-6811	average	_
38-27	6812-6815	6.1	_
38-28	6816-6817	s	_
38-29	6818-6819	)	_
38-30	6820-6821	.	_

39-1	6822-6825	The	_
39-2	6826-6833	overall	_
39-3	6834-6843	durations	_
39-4	6844-6846	of	_
39-5	6847-6850	all	_
39-6	6851-6858	stimuli	_
39-7	6859-6863	were	_
39-8	6864-6873	identical	_
39-9	6874-6875	.	_

40-1	6876-6877	3	_
40-2	6878-6886	s–silent	_
40-3	6887-6894	periods	_
40-4	6895-6903	preceded	_
40-5	6904-6907	and	_
40-6	6908-6916	followed	_
40-7	6917-6921	each	_
40-8	6922-6931	condition	_
40-9	6932-6935	and	_
40-10	6936-6940	were	_
40-11	6941-6950	discarded	_
40-12	6951-6955	from	_
40-13	6956-6959	all	_
40-14	6960-6968	analyses	_
40-15	6969-6970	.	_

41-1	6971-6972	A	_
41-2	6973-6980	typical	_
41-3	6981-6988	session	_
41-4	6989-6995	lasted	_
41-5	6996-7001	about	_
41-6	7002-7004	45	_
41-7	7005-7008	min	_
41-8	7009-7012	and	_
41-9	7013-7016	was	_
41-10	7017-7026	comprised	_
41-11	7027-7029	of	_
41-12	7030-7035	three	_
41-13	7036-7046	functional	_
41-14	7047-7051	runs	_
41-15	7052-7053	,	_
41-16	7054-7058	each	_
41-17	7059-7069	consisting	_
41-18	7070-7072	of	_
41-19	7073-7076	the	_
41-20	7077-7089	presentation	_
41-21	7090-7092	of	_
41-22	7093-7096	one	_
41-23	7097-7106	condition	_
41-24	7107-7108	(	_
41-25	7109-7114	8-min	_
41-26	7115-7119	each	_
41-27	7120-7121	)	_
41-28	7122-7123	.	_

42-1	7124-7127	The	_
42-2	7128-7140	presentation	_
42-3	7141-7146	order	_
42-4	7147-7149	of	_
42-5	7150-7160	conditions	_
42-6	7161-7167	within	_
42-7	7168-7169	a	_
42-8	7170-7177	session	_
42-9	7178-7181	was	_
42-10	7182-7192	randomized	_
42-11	7193-7199	across	_
42-12	7200-7212	participants	_
42-13	7213-7214	.	_

43-1	7215-7220	Short	_
43-2	7221-7226	2-min	_
43-3	7227-7233	breaks	_
43-4	7234-7238	were	_
43-5	7239-7250	implemented	_
43-6	7251-7258	between	_
43-7	7259-7262	the	_
43-8	7263-7273	functional	_
43-9	7274-7277	and	_
43-10	7278-7288	structural	_
43-11	7289-7294	scans	_
43-12	7295-7297	to	_
43-13	7298-7304	verify	_
43-14	7305-7317	participants	_
43-15	7318-7319	'	_
43-16	7320-7330	well-being	_
43-17	7331-7334	and	_
43-18	7335-7344	awareness	_
43-19	7345-7348	and	_
43-20	7349-7351	to	_
43-21	7352-7357	allow	_
43-22	7358-7362	them	_
43-23	7363-7365	to	_
43-24	7366-7371	relax	_
43-25	7372-7373	.	_

44-1	7374-7383	Attentive	_
44-2	7384-7393	listening	_
44-3	7394-7397	was	_
44-4	7398-7407	confirmed	_
44-5	7408-7410	by	_
44-6	7411-7416	brief	_
44-7	7417-7430	communication	_
44-8	7431-7435	with	_
44-9	7436-7448	participants	_
44-10	7449-7456	between	_
44-11	7457-7461	runs	_
44-12	7462-7463	.	_

45-1	7464-7466	At	_
45-2	7467-7470	the	_
45-3	7471-7474	end	_
45-4	7475-7477	of	_
45-5	7478-7481	the	_
45-6	7482-7489	session	_
45-7	7490-7491	,	_
45-8	7492-7499	outside	_
45-9	7500-7503	the	_
45-10	7504-7511	scanner	_
45-11	7512-7513	,	_
45-12	7514-7526	participants	_
45-13	7527-7531	were	_
45-14	7532-7537	asked	_
45-15	7538-7540	to	_
45-16	7541-7549	describe	_
45-17	7550-7553	the	_
45-18	7554-7558	main	_
45-19	7559-7563	plot	_
45-20	7564-7566	of	_
45-21	7567-7570	the	_
45-22	7571-7576	story	_
45-23	7577-7578	.	_

46-1	7579-7597	Neuropsychological	_
46-2	7598-7608	assessment	_
46-3	7609-7612	All	_
46-4	7613-7625	participants	_
46-5	7626-7630	were	_
46-6	7631-7639	screened	_
46-7	7640-7642	by	_
46-8	7643-7644	a	_
46-9	7645-7663	neuropsychological	_
46-10	7664-7674	assessment	_
46-11	7675-7680	which	_
46-12	7681-7689	included	_
46-13	7690-7693	the	_
46-14	7694-7702	Montreal	_
46-15	7703-7712	Cognitive	_
46-16	7713-7723	Assessment	_
46-17	7724-7725	(	_
46-18	7726-7730	MoCA	_
46-19	7731-7732	)	_
46-20	7733-7736	and	_
46-21	7737-7749	standardized	_
46-22	7750-7755	tests	_
46-23	7756-7758	of	_
46-24	7759-7763	text	_
46-25	7764-7777	comprehension	_
46-26	7778-7779	.	_

47-1	7780-7782	In	_
47-2	7783-7786	the	_
47-3	7787-7791	text	_
47-4	7792-7805	comprehension	_
47-5	7806-7811	tests	_
47-6	7812-7824	participants	_
47-7	7825-7829	were	_
47-8	7830-7839	presented	_
47-9	7840-7844	with	_
47-10	7845-7850	short	_
47-11	7851-7858	stories	_
47-12	7859-7862	and	_
47-13	7863-7875	subsequently	_
47-14	7876-7884	required	_
47-15	7885-7887	to	_
47-16	7888-7894	recall	_
47-17	7895-7899	them	_
47-18	7900-7902	in	_
47-19	7903-7905	as	_
47-20	7906-7910	much	_
47-21	7911-7917	detail	_
47-22	7918-7920	as	_
47-23	7921-7929	possible	_
47-24	7930-7931	.	_

48-1	7932-7935	The	_
48-2	7936-7940	text	_
48-3	7941-7954	comprehension	_
48-4	7955-7960	tests	_
48-5	7961-7965	were	_
48-6	7966-7975	evaluated	_
48-7	7976-7978	on	_
48-8	7979-7980	a	_
48-9	7981-7988	4-point	_
48-10	7989-7994	scale	_
48-11	7995-7996	;	_
48-12	7997-7998	1	_
48-13	7999-8000	=	_
48-14	8001-8004	not	_
48-15	8005-8007	at	_
48-16	8008-8011	all	_
48-17	8012-8013	,	_
48-18	8014-8015	4	_
48-19	8016-8017	=	_
48-20	8018-8025	perfect	_
48-21	8026-8039	understanding	_
48-22	8040-8041	.	_

49-1	8042-8045	The	_
49-2	8046-8052	scores	_
49-3	8053-8056	for	_
49-4	8057-8060	the	_
49-5	8061-8065	MoCA	_
49-6	8066-8067	(	_
49-7	8068-8078	separately	_
49-8	8079-8082	for	_
49-9	8083-8086	the	_
49-10	8087-8094	subsets	_
49-11	8095-8097	of	_
49-12	8098-8101	the	_
49-13	8102-8106	test	_
49-14	8107-8108	)	_
49-15	8109-8110	,	_
49-16	8111-8121	indicating	_
49-17	8122-8129	correct	_
49-18	8130-8139	responses	_
49-19	8140-8143	and	_
49-20	8144-8150	scores	_
49-21	8151-8154	for	_
49-22	8155-8158	the	_
49-23	8159-8163	text	_
49-24	8164-8177	comprehension	_
49-25	8178-8179	,	_
49-26	8180-8190	indicating	_
49-27	8191-8196	level	_
49-28	8197-8199	of	_
49-29	8200-8213	understanding	_
49-30	8214-8217	are	_
49-31	8218-8223	shown	_
49-32	8224-8226	in	_
49-33	8227-8232	Table	_
49-34	8233-8235	2A	_
49-35	8236-8237	.	_

50-1	8238-8249	Statistical	_
50-2	8250-8260	comparison	_
50-3	8261-8264	for	_
50-4	8265-8278	between-group	_
50-5	8279-8290	differences	_
50-6	8291-8293	in	_
50-7	8294-8312	neuropsychological	_
50-8	8313-8323	assessment	_
50-9	8324-8329	using	_
50-10	8330-8333	the	_
50-11	8334-8353	Kolmogorov-Smirnoff	_
50-12	8354-8358	test	_
50-13	8359-8361	is	_
50-14	8362-8370	provided	_
50-15	8371-8373	in	_
50-16	8374-8379	Table	_
50-17	8380-8382	2B	_
50-18	8383-8384	.	_

51-1	8385-8389	Data	_
51-2	8390-8398	analysis	_
51-3	8399-8412	Preprocessing	_
51-4	8413-8427	BrainVoyagerQX	_
51-5	8428-8431	2.4	_
51-6	8432-8433	(	_
51-7	8434-8439	Brain	_
51-8	8440-8450	Innovation	_
51-9	8451-8452	,	_
51-10	8453-8463	Maastricht	_
51-11	8464-8465	,	_
51-12	8466-8469	The	_
51-13	8470-8481	Netherlands	_
51-14	8482-8483	)	_
51-15	8484-8487	was	_
51-16	8488-8492	used	_
51-17	8493-8496	for	_
51-18	8497-8510	preprocessing	_
51-19	8511-8514	and	_
51-20	8515-8530	co-registration	_
51-21	8531-8533	of	_
51-22	8534-8537	the	_
51-23	8538-8550	standardized	_
51-24	8551-8561	anatomical	_
51-25	8562-8565	and	_
51-26	8566-8576	functional	_
51-27	8577-8581	data	_
51-28	8582-8583	.	_

52-1	8584-8588	Data	_
52-2	8589-8597	analysis	_
52-3	8598-8601	was	_
52-4	8602-8611	performed	_
52-5	8612-8622	separately	_
52-6	8623-8626	for	_
52-7	8627-8631	each	_
52-8	8632-8643	participant	_
52-9	8644-8645	.	_

53-1	8646-8649	The	_
53-2	8650-8654	data	_
53-3	8655-8659	were	_
53-4	8660-8664	high	_
53-5	8665-8669	pass	_
53-6	8670-8678	filtered	_
53-7	8679-8681	at	_
53-8	8682-8687	0.008	_
53-9	8688-8690	Hz	_
53-10	8691-8694	and	_
53-11	8695-8704	spatially	_
53-12	8705-8713	smoothed	_
53-13	8714-8718	with	_
53-14	8719-8720	a	_
53-15	8721-8722	6	_
53-16	8723-8725	mm	_
53-17	8726-8730	full	_
53-18	8731-8736	width	_
53-19	8737-8739	at	_
53-20	8740-8744	half	_
53-21	8745-8752	maximum	_
53-22	8753-8754	(	_
53-23	8755-8759	FWHM	_
53-24	8760-8761	)	_
53-25	8762-8768	kernel	_
53-26	8769-8770	.	_

54-1	8771-8773	To	_
54-2	8774-8779	avoid	_
54-3	8780-8783	the	_
54-4	8784-8795	confounding	_
54-5	8796-8802	effect	_
54-6	8803-8805	of	_
54-7	8806-8818	fluctuations	_
54-8	8819-8821	in	_
54-9	8822-8825	the	_
54-10	8826-8837	whole-brain	_
54-11	8838-8856	blood-oxygen-level	_
54-12	8857-8866	dependent	_
54-13	8867-8868	(	_
54-14	8869-8873	BOLD	_
54-15	8874-8875	)	_
54-16	8876-8882	signal	_
54-17	8883-8884	,	_
54-18	8885-8888	for	_
54-19	8889-8893	each	_
54-20	8894-8896	TR	_
54-21	8897-8898	,	_
54-22	8899-8903	each	_
54-23	8904-8909	voxel	_
54-24	8910-8913	was	_
54-25	8914-8920	scaled	_
54-26	8921-8923	by	_
54-27	8924-8927	the	_
54-28	8928-8934	global	_
54-29	8935-8939	mean	_
54-30	8940-8942	at	_
54-31	8943-8947	that	_
54-32	8948-8952	time	_
54-33	8953-8958	point	_
54-34	8959-8960	.	_

55-1	8961-8965	Head	_
55-2	8966-8973	motions	_
55-3	8974-8978	were	_
55-4	8979-8987	detected	_
55-5	8988-8991	and	_
55-6	8992-9001	corrected	_
55-7	9002-9007	using	_
55-8	9008-9017	trilinear	_
55-9	9018-9021	and	_
55-10	9022-9026	sinc	_
55-11	9027-9041	interpolations	_
55-12	9042-9043	,	_
55-13	9044-9056	respectively	_
55-14	9057-9058	.	_

56-1	9059-9062	Due	_
56-2	9063-9065	to	_
56-3	9066-9075	extensive	_
56-4	9076-9080	head	_
56-5	9081-9090	movements	_
56-6	9091-9092	(	_
56-7	9093-9103	deviations	_
56-8	9104-9110	higher	_
56-9	9111-9115	than	_
56-10	9116-9123	1.5°/mm	_
56-11	9124-9132	relative	_
56-12	9133-9135	to	_
56-13	9136-9139	the	_
56-14	9140-9149	reference	_
56-15	9150-9151	)	_
56-16	9152-9153	1	_
56-17	9154-9161	patient	_
56-18	9162-9163	,	_
56-19	9164-9165	5	_
56-20	9166-9173	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
56-21	9174-9182	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
56-22	9183-9186	and	_
56-23	9187-9188	1	_
56-24	9189-9196	sibling	_
56-25	9197-9201	were	_
56-26	9202-9210	excluded	_
56-27	9211-9215	from	_
56-28	9216-9219	the	_
56-29	9220-9225	study	_
56-30	9226-9227	.	_

57-1	9228-9231	The	_
57-2	9232-9240	cortical	_
57-3	9241-9248	surface	_
57-4	9249-9252	was	_
57-5	9253-9266	reconstructed	_
57-6	9267-9271	from	_
57-7	9272-9275	the	_
57-8	9276-9286	anatomical	_
57-9	9287-9293	images	_
57-10	9294-9299	using	_
57-11	9300-9308	standard	_
57-12	9309-9319	procedures	_
57-13	9320-9331	implemented	_
57-14	9332-9334	in	_
57-15	9335-9338	the	_
57-16	9339-9351	BrainVoyager	_
57-17	9352-9360	software	_
57-18	9361-9362	.	_

58-1	9363-9366	The	_
58-2	9367-9375	complete	_
58-3	9376-9386	functional	_
58-4	9387-9394	dataset	_
58-5	9395-9398	was	_
58-6	9399-9410	transformed	_
58-7	9411-9413	to	_
58-8	9414-9415	a	_
58-9	9416-9422	common	_
58-10	9423-9425	3D	_
58-11	9426-9435	Talairach	_
58-12	9436-9441	space	_
58-13	9442-9445	and	_
58-14	9446-9455	projected	_
58-15	9456-9458	on	_
58-16	9459-9460	a	_
58-17	9461-9475	reconstruction	_
58-18	9476-9478	of	_
58-19	9479-9482	the	_
58-20	9483-9491	cortical	_
58-21	9492-9499	surface	_
58-22	9500-9501	.	_

59-1	9502-9510	Inter-SC	_
59-2	9511-9519	analysis	_
59-3	9520-9524	Data	_
59-4	9525-9529	were	_
59-5	9530-9538	analyzed	_
59-6	9539-9544	using	_
59-7	9545-9548	the	_
59-8	9549-9557	inter-SC	_
59-9	9558-9566	approach	_
59-10	9567-9568	,	_
59-11	9569-9578	measuring	_
59-12	9579-9589	similarity	_
59-13	9590-9592	of	_
59-14	9593-9599	neural	_
59-15	9600-9609	responses	_
59-16	9610-9616	across	_
59-17	9617-9628	individuals	_
59-18	9629-9632	who	_
59-19	9633-9636	are	_
59-20	9637-9646	presented	_
59-21	9647-9651	with	_
59-22	9652-9655	the	_
59-23	9656-9660	same	_
59-24	9661-9668	stimuli	_
59-25	9669-9670	.	_

60-1	9671-9674	For	_
60-2	9675-9679	each	_
60-3	9680-9685	voxel	_
60-4	9686-9687	,	_
60-5	9688-9696	inter-SC	_
60-6	9697-9700	was	_
60-7	9701-9711	calculated	_
60-8	9712-9714	as	_
60-9	9715-9717	an	_
60-10	9718-9725	average	_
60-11	9726-9727	,	_
60-12	9728-9733	where	_
60-13	9734-9737	the	_
60-14	9738-9748	individual	_
60-15	9749-9751	rj	_
60-16	9752-9755	are	_
60-17	9756-9759	the	_
60-18	9760-9767	Pearson	_
60-19	9768-9782	product-moment	_
60-20	9783-9795	correlations	_
60-21	9796-9803	between	_
60-22	9804-9808	that	_
60-23	9809-9814	voxel	_
60-24	9815-9817	's	_
60-25	9818-9822	BOLD	_
60-26	9823-9827	time	_
60-27	9828-9834	course	_
60-28	9835-9837	in	_
60-29	9838-9841	one	_
60-30	9842-9852	individual	_
60-31	9853-9856	and	_
60-32	9857-9860	the	_
60-33	9861-9868	average	_
60-34	9869-9871	of	_
60-35	9872-9876	that	_
60-36	9877-9882	voxel	_
60-37	9883-9885	's	_
60-38	9886-9890	BOLD	_
60-39	9891-9895	time	_
60-40	9896-9903	courses	_
60-41	9904-9906	in	_
60-42	9907-9910	the	_
60-43	9911-9920	remaining	_
60-44	9921-9932	individuals	_
60-45	9933-9934	.	_

61-1	9935-9943	Inter-SC	_
61-2	9944-9948	maps	_
61-3	9949-9953	were	_
61-4	9954-9965	constructed	_
61-5	9966-9976	separately	_
61-6	9977-9980	for	_
61-7	9981-9991	conditions	_
61-8	9992-9993	,	_
61-9	9994-10000	within	_
61-10	10001-10007	groups	_
61-11	10008-10009	(	_
61-12	10010-10013	Fig	_
61-13	10014-10015	.	_

62-1	10016-10019	1B1	_
62-2	10020-10021	&	_
62-3	10022-10025	Fig	_
62-4	10026-10027	.	_

63-1	10028-10029	2	_
63-2	10030-10031	)	_
63-3	10032-10035	and	_
63-4	10036-10043	between	_
63-5	10044-10050	groups	_
63-6	10051-10052	(	_
63-7	10053-10056	Fig	_
63-8	10057-10058	.	_

64-1	10059-10062	1B3	_
64-2	10063-10064	&	_
64-3	10065-10068	Fig	_
64-4	10069-10070	.	_

65-1	10071-10072	5	_
65-2	10073-10074	)	_
65-3	10075-10076	.	_

66-1	10077-10081	Only	_
66-2	10082-10088	voxels	_
66-3	10089-10093	that	_
66-4	10094-10100	passed	_
66-5	10101-10112	statistical	_
66-6	10113-10125	significance	_
66-7	10126-10130	test	_
66-8	10131-10132	(	_
66-9	10133-10136	see	_
66-10	10137-10140	the	_
66-11	10141-10150	following	_
66-12	10151-10160	paragraph	_
66-13	10161-10162	)	_
66-14	10163-10167	were	_
66-15	10168-10173	shown	_
66-16	10174-10176	on	_
66-17	10177-10180	the	_
66-18	10181-10185	maps	_
66-19	10186-10187	.	_

67-1	10188-10199	Controlling	_
67-2	10200-10203	for	_
67-3	10204-10209	false	_
67-4	10210-10219	positives	_
67-5	10220-10231	Statistical	_
67-6	10232-10244	significance	_
67-7	10245-10247	of	_
67-8	10248-10260	correlations	_
67-9	10261-10264	was	_
67-10	10265-10273	assessed	_
67-11	10274-10279	using	_
67-12	10280-10281	a	_
67-13	10282-10295	bootstrapping	_
67-14	10296-10305	procedure	_
67-15	10306-10311	based	_
67-16	10312-10314	on	_
67-17	10315-10334	phase-randomization	_
67-18	10335-10336	.	_

68-1	10337-10340	The	_
68-2	10341-10345	null	_
68-3	10346-10356	hypothesis	_
68-4	10357-10360	was	_
68-5	10361-10365	that	_
68-6	10366-10369	the	_
68-7	10370-10374	BOLD	_
68-8	10375-10381	signal	_
68-9	10382-10384	in	_
68-10	10385-10389	each	_
68-11	10390-10395	voxel	_
68-12	10396-10398	in	_
68-13	10399-10403	each	_
68-14	10404-10415	participant	_
68-15	10416-10419	was	_
68-16	10420-10431	independent	_
68-17	10432-10434	of	_
68-18	10435-10438	the	_
68-19	10439-10443	BOLD	_
68-20	10444-10450	signal	_
68-21	10451-10457	values	_
68-22	10458-10460	in	_
68-23	10461-10464	the	_
68-24	10465-10478	corresponding	_
68-25	10479-10484	voxel	_
68-26	10485-10487	in	_
68-27	10488-10491	any	_
68-28	10492-10497	other	_
68-29	10498-10509	participant	_
68-30	10510-10512	at	_
68-31	10513-10516	any	_
68-32	10517-10522	point	_
68-33	10523-10525	in	_
68-34	10526-10530	time	_
68-35	10531-10532	(	_
68-36	10533-10537	i.e.	_
68-37	10538-10539	,	_
68-38	10540-10542	no	_
68-39	10543-10551	inter-SC	_
68-40	10552-10559	between	_
68-41	10560-10563	any	_
68-42	10564-10568	pair	_
68-43	10569-10571	of	_
68-44	10572-10583	individuals	_
68-45	10584-10585	)	_
68-46	10586-10587	.	_

69-1	10588-10591	For	_
69-2	10592-10595	all	_
69-3	10596-10606	conditions	_
69-4	10607-10608	,	_
69-5	10609-10610	a	_
69-6	10611-10630	phase-randomization	_
69-7	10631-10633	of	_
69-8	10634-10638	each	_
69-9	10639-10644	voxel	_
69-10	10645-10647	's	_
69-11	10648-10652	time	_
69-12	10653-10659	course	_
69-13	10660-10663	was	_
69-14	10664-10673	performed	_
69-15	10674-10676	by	_
69-16	10677-10685	applying	_
69-17	10686-10687	a	_
69-18	10688-10692	fast	_
69-19	10693-10700	Fourier	_
69-20	10701-10710	transform	_
69-21	10711-10713	to	_
69-22	10714-10717	the	_
69-23	10718-10724	signal	_
69-24	10725-10726	,	_
69-25	10727-10738	randomizing	_
69-26	10739-10742	the	_
69-27	10743-10748	phase	_
69-28	10749-10751	of	_
69-29	10752-10756	each	_
69-30	10757-10764	Fourier	_
69-31	10765-10774	component	_
69-32	10775-10776	,	_
69-33	10777-10780	and	_
69-34	10781-10790	inverting	_
69-35	10791-10794	the	_
69-36	10795-10802	Fourier	_
69-37	10803-10817	transformation	_
69-38	10818-10819	.	_

70-1	10820-10824	This	_
70-2	10825-10834	procedure	_
70-3	10835-10844	scrambles	_
70-4	10845-10848	the	_
70-5	10849-10854	phase	_
70-6	10855-10857	of	_
70-7	10858-10861	the	_
70-8	10862-10866	BOLD	_
70-9	10867-10871	time	_
70-10	10872-10879	courses	_
70-11	10880-10883	but	_
70-12	10884-10890	leaves	_
70-13	10891-10894	its	_
70-14	10895-10900	power	_
70-15	10901-10909	spectrum	_
70-16	10910-10916	intact	_
70-17	10917-10918	.	_

71-1	10919-10922	For	_
71-2	10923-10927	each	_
71-3	10928-10936	randomly	_
71-4	10937-10952	phase-scrambled	_
71-5	10953-10962	surrogate	_
71-6	10963-10970	dataset	_
71-7	10971-10972	,	_
71-8	10973-10975	we	_
71-9	10976-10984	computed	_
71-10	10985-10988	the	_
71-11	10989-10997	inter-SC	_
71-12	10998-11010	coefficients	_
71-13	11011-11014	for	_
71-14	11015-11018	all	_
71-15	11019-11025	voxels	_
71-16	11026-11028	in	_
71-17	11029-11032	the	_
71-18	11033-11038	exact	_
71-19	11039-11043	same	_
71-20	11044-11050	manner	_
71-21	11051-11053	as	_
71-22	11054-11057	the	_
71-23	11058-11067	empirical	_
71-24	11068-11079	correlation	_
71-25	11080-11084	maps	_
71-26	11085-11094	described	_
71-27	11095-11100	above	_
71-28	11101-11102	.	_

72-1	11103-11107	This	_
72-2	11108-11117	procedure	_
72-3	11118-11121	was	_
72-4	11122-11131	performed	_
72-5	11132-11136	5000	_
72-6	11137-11142	times	_
72-7	11143-11151	allowing	_
72-8	11152-11155	for	_
72-9	11156-11166	estimation	_
72-10	11167-11169	of	_
72-11	11170-11171	a	_
72-12	11172-11176	null	_
72-13	11177-11189	distribution	_
72-14	11190-11192	of	_
72-15	11193-11200	average	_
72-16	11201-11213	correlations	_
72-17	11214-11220	within	_
72-18	11221-11224	the	_
72-19	11225-11230	voxel	_
72-20	11231-11232	.	_

73-1	11233-11244	Statistical	_
73-2	11245-11257	significance	_
73-3	11258-11259	(	_
73-4	11260-11261	p	_
73-5	11262-11268	values	_
73-6	11269-11270	)	_
73-7	11271-11274	was	_
73-8	11275-11284	estimated	_
73-9	11285-11287	by	_
73-10	11288-11297	comparing	_
73-11	11298-11307	empirical	_
73-12	11308-11319	correlation	_
73-13	11320-11326	values	_
73-14	11327-11328	(	_
73-15	11329-11336	without	_
73-16	11337-11356	phase-randomization	_
73-17	11357-11358	)	_
73-18	11359-11361	to	_
73-19	11362-11367	these	_
73-20	11368-11372	null	_
73-21	11373-11386	distributions	_
73-22	11387-11389	as	_
73-23	11390-11391	a	_
73-24	11392-11402	percentile	_
73-25	11403-11407	from	_
73-26	11408-11411	the	_
73-27	11412-11417	tails	_
73-28	11418-11420	of	_
73-29	11421-11424	the	_
73-30	11425-11437	distribution	_
73-31	11438-11439	.	_

74-1	11440-11443	The	_
74-2	11444-11453	resulting	_
74-3	11454-11457	map	_
74-4	11458-11460	of	_
74-5	11461-11470	inter-SCs	_
74-6	11471-11474	was	_
74-7	11475-11484	corrected	_
74-8	11485-11488	for	_
74-9	11489-11497	multiple	_
74-10	11498-11509	comparisons	_
74-11	11510-11511	,	_
74-12	11512-11517	using	_
74-13	11518-11530	bootstrapped	_
74-14	11531-11532	p	_
74-15	11533-11539	values	_
74-16	11540-11542	by	_
74-17	11543-11546	The	_
74-18	11547-11556	Benjamini	_
74-19	11557-11558	–	_
74-20	11559-11567	Hochberg	_
74-21	11568-11569	–	_
74-22	11570-11579	Yekutieli	_
74-23	11580-11595	false-discovery	_
74-24	11596-11605	procedure	_
74-25	11606-11607	,	_
74-26	11608-11612	with	_
74-27	11613-11616	the	_
74-28	11617-11626	threshold	_
74-29	11627-11631	0.05	_
74-30	11632-11633	.	_

75-1	11634-11644	Comparison	_
75-2	11645-11652	between	_
75-3	11653-11659	groups	_
75-4	11660-11662	To	_
75-5	11663-11667	test	_
75-6	11668-11671	the	_
75-7	11672-11683	differences	_
75-8	11684-11691	between	_
75-9	11692-11698	groups	_
75-10	11699-11700	,	_
75-11	11701-11702	a	_
75-12	11703-11713	two-tailed	_
75-13	11714-11720	t-test	_
75-14	11721-11724	was	_
75-15	11725-11734	performed	_
75-16	11735-11741	within	_
75-17	11742-11746	each	_
75-18	11747-11752	voxel	_
75-19	11753-11757	that	_
75-20	11758-11764	showed	_
75-21	11765-11776	significant	_
75-22	11777-11787	difference	_
75-23	11788-11790	of	_
75-24	11791-11799	inter-SC	_
75-25	11800-11806	values	_
75-26	11807-11809	in	_
75-27	11810-11812	at	_
75-28	11813-11818	least	_
75-29	11819-11822	one	_
75-30	11823-11825	of	_
75-31	11826-11829	the	_
75-32	11830-11839	inspected	_
75-33	11840-11846	groups	_
75-34	11847-11848	.	_

76-1	11849-11852	The	_
76-2	11853-11864	voxel-wised	_
76-3	11865-11871	t-test	_
76-4	11872-11875	was	_
76-5	11876-11880	done	_
76-6	11881-11883	by	_
76-7	11884-11893	comparing	_
76-8	11894-11897	the	_
76-9	11898-11916	Fisher-transformed	_
76-10	11917-11928	correlation	_
76-11	11929-11935	values	_
76-12	11936-11944	computed	_
76-13	11945-11947	in	_
76-14	11948-11952	each	_
76-15	11953-11958	voxel	_
76-16	11959-11961	of	_
76-17	11962-11974	participants	_
76-18	11975-11979	from	_
76-19	11980-11989	different	_
76-20	11990-11996	groups	_
76-21	11997-11998	.	_

77-1	11999-12001	In	_
77-2	12002-12007	other	_
77-3	12008-12013	words	_
77-4	12014-12015	,	_
77-5	12016-12026	two-tailed	_
77-6	12027-12034	t-tests	_
77-7	12035-12039	were	_
77-8	12040-12048	employed	_
77-9	12049-12051	to	_
77-10	12052-12056	show	_
77-11	12057-12060	the	_
77-12	12061-12066	brain	_
77-13	12067-12074	regions	_
77-14	12075-12079	that	_
77-15	12080-12083	had	_
77-16	12084-12088	more	_
77-17	12089-12099	consistent	_
77-18	12100-12102	or	_
77-19	12103-12107	less	_
77-20	12108-12118	consistent	_
77-21	12119-12128	responses	_
77-22	12129-12136	between	_
77-23	12137-12143	groups	_
77-24	12144-12145	(	_
77-25	12146-12149	Fig	_
77-26	12150-12151	.	_

78-1	12152-12155	1B2	_
78-2	12156-12157	&	_
78-3	12158-12161	Fig	_
78-4	12162-12163	.	_

79-1	12164-12165	3	_
79-2	12166-12167	)	_
79-3	12168-12169	.	_

80-1	12170-12179	Selection	_
80-2	12180-12182	of	_
80-3	12183-12190	regions	_
80-4	12191-12193	of	_
80-5	12194-12202	interest	_
80-6	12203-12204	(	_
80-7	12205-12209	ROIs	_
80-8	12210-12211	)	_
80-9	12212-12216	with	_
80-10	12217-12226	different	_
80-11	12227-12237	processing	_
80-12	12238-12242	time	_
80-13	12243-12249	scales	_
80-14	12250-12258	Although	_
80-15	12259-12262	all	_
80-16	12263-12266	our	_
80-17	12267-12274	healthy	_
80-18	12275-12287	participants	_
80-19	12288-12297	exhibited	_
80-20	12298-12308	consistent	_
80-21	12309-12313	time	_
80-22	12314-12319	scale	_
80-23	12320-12330	topography	_
80-24	12331-12332	,	_
80-25	12333-12344	identifying	_
80-26	12345-12348	the	_
80-27	12349-12353	ROIs	_
80-28	12354-12359	based	_
80-29	12360-12362	on	_
80-30	12363-12368	these	_
80-31	12369-12373	data	_
80-32	12374-12379	would	_
80-33	12380-12384	bias	_
80-34	12385-12388	the	_
80-35	12389-12397	analyses	_
80-36	12398-12404	toward	_
80-37	12405-12408	the	_
80-38	12409-12416	healthy	_
80-39	12417-12424	control	_
80-40	12425-12430	group	_
80-41	12431-12432	.	_

81-1	12433-12442	Therefore	_
81-2	12443-12444	,	_
81-3	12445-12447	we	_
81-4	12448-12455	defined	_
81-5	12456-12459	the	_
81-6	12460-12467	average	_
81-7	12468-12472	ROIs	_
81-8	12473-12477	with	_
81-9	12478-12483	short	_
81-10	12484-12485	,	_
81-11	12486-12498	intermediate	_
81-12	12499-12502	and	_
81-13	12503-12507	long	_
81-14	12508-12516	temporal	_
81-15	12517-12523	scales	_
81-16	12524-12528	from	_
81-17	12529-12530	a	_
81-18	12531-12539	separate	_
81-19	12540-12541	,	_
81-20	12542-12553	independent	_
81-21	12554-12559	group	_
81-22	12560-12562	of	_
81-23	12563-12565	12	_
81-24	12566-12573	healthy	_
81-25	12574-12586	participants	_
81-26	12587-12588	.	_

82-1	12589-12601	Specifically	_
82-2	12602-12603	,	_
82-3	12604-12607	the	_
82-4	12608-12616	temporal	_
82-5	12617-12622	scale	_
82-6	12623-12625	of	_
82-7	12626-12630	each	_
82-8	12631-12634	ROI	_
82-9	12635-12637	in	_
82-10	12638-12642	this	_
82-11	12643-12648	group	_
82-12	12649-12652	was	_
82-13	12653-12660	defined	_
82-14	12661-12670	according	_
82-15	12671-12673	to	_
82-16	12674-12677	the	_
82-17	12678-12686	response	_
82-18	12687-12698	reliability	_
82-19	12699-12701	in	_
82-20	12702-12706	that	_
82-21	12707-12713	region	_
82-22	12714-12720	across	_
82-23	12721-12728	stimuli	_
82-24	12729-12738	scrambled	_
82-25	12739-12741	on	_
82-26	12742-12745	the	_
82-27	12746-12760	aforementioned	_
82-28	12761-12770	different	_
82-29	12771-12775	time	_
82-30	12776-12782	scales	_
82-31	12783-12784	(	_
82-32	12785-12788	for	_
82-33	12789-12796	details	_
82-34	12797-12800	see	_
82-35	12801-12802	)	_
82-36	12803-12804	.	_

83-1	12805-12808	The	_
83-2	12809-12820	coordinates	_
83-3	12821-12823	of	_
83-4	12824-12829	these	_
83-5	12830-12834	ROIs	_
83-6	12835-12839	were	_
83-7	12840-12847	applied	_
83-8	12848-12850	to	_
83-9	12851-12857	derive	_
83-10	12858-12862	ROIs	_
83-11	12863-12865	in	_
83-12	12866-12870	each	_
83-13	12871-12882	participant	_
83-14	12883-12885	in	_
83-15	12886-12889	the	_
83-16	12890-12897	current	_
83-17	12898-12903	study	_
83-18	12904-12905	.	_

84-1	12906-12912	Namely	_
84-2	12913-12914	,	_
84-3	12915-12919	ROIs	_
84-4	12920-12924	with	_
84-5	12925-12926	a	_
84-6	12927-12936	predicted	_
84-7	12937-12941	time	_
84-8	12942-12947	scale	_
84-9	12948-12952	were	_
84-10	12953-12961	selected	_
84-11	12962-12963	:	_
84-12	12964-12970	middle	_
84-13	12971-12979	superior	_
84-14	12980-12988	temporal	_
84-15	12989-12994	gyrus	_
84-16	12995-12996	(	_
84-17	12997-13001	mSTG	_
84-18	13002-13003	)	_
84-19	13004-13005	,	_
84-20	13006-13023	temporal-parietal	_
84-21	13024-13032	junction	_
84-22	13033-13034	(	_
84-23	13035-13038	TPJ	_
84-24	13039-13040	)	_
84-25	13041-13042	,	_
84-26	13043-13048	DLPFC	_
84-27	13049-13050	,	_
84-28	13051-13057	medial	_
84-29	13058-13068	prefrontal	_
84-30	13069-13075	cortex	_
84-31	13076-13077	(	_
84-32	13078-13082	mPFC	_
84-33	13083-13084	)	_
84-34	13085-13088	and	_
84-35	13089-13098	precuneus	_
84-36	13099-13100	(	_
84-37	13101-13104	Fig	_
84-38	13105-13106	.	_

85-1	13107-13110	1B4	_
85-2	13111-13112	&	_
85-3	13113-13116	Fig	_
85-4	13117-13118	.	_

86-1	13119-13120	4	_
86-2	13121-13122	)	_
86-3	13123-13124	.	_

87-1	13125-13127	An	_
87-2	13128-13133	early	_
87-3	13134-13142	auditory	_
87-4	13143-13146	ROI	_
87-5	13147-13148	(	_
87-6	13149-13152	A1+	_
87-7	13153-13154	)	_
87-8	13155-13158	was	_
87-9	13159-13166	defined	_
87-10	13167-13169	as	_
87-11	13170-13173	the	_
87-12	13174-13177	set	_
87-13	13178-13180	of	_
87-14	13181-13187	voxels	_
87-15	13188-13192	that	_
87-16	13193-13203	correlated	_
87-17	13204-13207	the	_
87-18	13208-13212	most	_
87-19	13213-13217	with	_
87-20	13218-13221	the	_
87-21	13222-13230	stimulus	_
87-22	13231-13236	audio	_
87-23	13237-13245	envelope	_
87-24	13246-13247	.	_

88-1	13248-13250	To	_
88-2	13251-13258	compute	_
88-3	13259-13262	the	_
88-4	13263-13274	correlation	_
88-5	13275-13282	between	_
88-6	13283-13287	BOLD	_
88-7	13288-13295	signals	_
88-8	13296-13299	and	_
88-9	13300-13303	the	_
88-10	13304-13309	audio	_
88-11	13310-13318	envelope	_
88-12	13319-13320	,	_
88-13	13321-13323	we	_
88-14	13324-13334	bandpassed	_
88-15	13335-13338	the	_
88-16	13339-13344	audio	_
88-17	13345-13351	signal	_
88-18	13352-13359	between	_
88-19	13360-13361	4	_
88-20	13362-13365	and	_
88-21	13366-13370	4000	_
88-22	13371-13373	Hz	_
88-23	13374-13375	,	_
88-24	13376-13385	extracted	_
88-25	13386-13389	the	_
88-26	13390-13398	envelope	_
88-27	13399-13401	of	_
88-28	13402-13405	the	_
88-29	13406-13412	signal	_
88-30	13413-13418	using	_
88-31	13419-13420	a	_
88-32	13421-13428	Hilbert	_
88-33	13429-13438	transform	_
88-34	13439-13440	,	_
88-35	13441-13444	and	_
88-36	13445-13449	then	_
88-37	13450-13461	downsampled	_
88-38	13462-13465	the	_
88-39	13466-13474	envelope	_
88-40	13475-13477	to	_
88-41	13478-13481	the	_
88-42	13482-13490	sampling	_
88-43	13491-13495	rate	_
88-44	13496-13498	of	_
88-45	13499-13502	the	_
88-46	13503-13507	BOLD	_
88-47	13508-13514	signal	_
88-48	13515-13520	using	_
88-49	13521-13523	an	_
88-50	13524-13537	anti-aliasing	_
88-51	13538-13546	low-pass	_
88-52	13547-13553	finite	_
88-53	13554-13561	impulse	_
88-54	13562-13570	response	_
88-55	13571-13577	filter	_
88-56	13578-13579	.	_

89-1	13580-13585	Table	_
89-2	13586-13587	3	_
89-3	13588-13596	provides	_
89-4	13597-13606	Talairach	_
89-5	13607-13618	coordinates	_
89-6	13619-13622	for	_
89-7	13623-13626	the	_
89-8	13627-13634	centers	_
89-9	13635-13637	of	_
89-10	13638-13641	the	_
89-11	13642-13647	noted	_
89-12	13648-13655	regions	_
89-13	13656-13657	.	_

90-1	13658-13660	In	_
90-2	13661-13669	addition	_
90-3	13670-13671	,	_
90-4	13672-13674	to	_
90-5	13675-13682	confirm	_
90-6	13683-13687	that	_
90-7	13688-13691	our	_
90-8	13692-13698	method	_
90-9	13699-13701	of	_
90-10	13702-13705	ROI	_
90-11	13706-13715	selection	_
90-12	13716-13720	does	_
90-13	13721-13724	not	_
90-14	13725-13729	bias	_
90-15	13730-13732	in	_
90-16	13733-13738	favor	_
90-17	13739-13741	of	_
90-18	13742-13749	healthy	_
90-19	13750-13762	participants	_
90-20	13763-13764	,	_
90-21	13765-13770	while	_
90-22	13771-13777	brains	_
90-23	13778-13780	in	_
90-24	13781-13789	patients	_
90-25	13790-13794	with	_
90-26	13795-13808	schizophrenia	_
90-27	13809-13812	are	_
90-28	13813-13826	characterized	_
90-29	13827-13829	by	_
90-30	13830-13838	cortical	_
90-31	13839-13846	atrophy	_
90-32	13847-13848	,	_
90-33	13849-13851	we	_
90-34	13852-13859	defined	_
90-35	13860-13867	another	_
90-36	13868-13871	set	_
90-37	13872-13874	of	_
90-38	13875-13879	ROIs	_
90-39	13880-13881	–	_
90-40	13882-13885	A1+	_
90-41	13886-13887	,	_
90-42	13888-13892	mSTG	_
90-43	13893-13894	,	_
90-44	13895-13898	TPJ	_
90-45	13899-13902	and	_
90-46	13903-13912	precuneus	_
90-47	13913-13918	based	_
90-48	13919-13921	on	_
90-49	13922-13925	the	_
90-50	13926-13935	responses	_
90-51	13936-13944	obtained	_
90-52	13945-13947	in	_
90-53	13948-13951	our	_
90-54	13952-13960	patients	_
90-55	13961-13965	with	_
90-56	13966-13979	schizophrenia	_
90-57	13980-13983	for	_
90-58	13984-13987	the	_
90-59	13988-13992	same	_
90-60	13993-14000	stimuli	_
90-61	14001-14002	.	_

91-1	14003-14007	This	_
91-2	14008-14017	procedure	_
91-3	14018-14021	for	_
91-4	14022-14025	ROI	_
91-5	14026-14035	selection	_
91-6	14036-14045	certainly	_
91-7	14046-14052	biased	_
91-8	14053-14056	the	_
91-9	14057-14066	responses	_
91-10	14067-14073	toward	_
91-11	14074-14077	the	_
91-12	14078-14086	patients	_
91-13	14087-14092	group	_
91-14	14093-14094	,	_
91-15	14095-14098	but	_
91-16	14099-14102	the	_
91-17	14103-14111	outcomes	_
91-18	14112-14116	were	_
91-19	14117-14124	similar	_
91-20	14125-14127	to	_
91-21	14128-14136	previous	_
91-22	14137-14144	results	_
91-23	14145-14149	with	_
91-24	14150-14151	a	_
91-25	14152-14155	set	_
91-26	14156-14158	of	_
91-27	14159-14172	independently	_
91-28	14173-14180	defined	_
91-29	14181-14185	ROIs	_
91-30	14186-14187	.	_

92-1	14188-14196	Response	_
92-2	14197-14206	amplitude	_
92-3	14207-14210	Due	_
92-4	14211-14213	to	_
92-5	14214-14217	the	_
92-6	14218-14224	nature	_
92-7	14225-14227	of	_
92-8	14228-14231	our	_
92-9	14232-14244	experimental	_
92-10	14245-14251	design	_
92-11	14252-14253	(	_
92-12	14254-14264	continuous	_
92-13	14265-14274	real-life	_
92-14	14275-14282	stimuli	_
92-15	14283-14284	)	_
92-16	14285-14286	,	_
92-17	14287-14289	we	_
92-18	14290-14293	can	_
92-19	14294-14297	not	_
92-20	14298-14306	directly	_
92-21	14307-14313	assess	_
92-22	14314-14321	changes	_
92-23	14322-14324	in	_
92-24	14325-14333	response	_
92-25	14334-14343	amplitude	_
92-26	14344-14352	relative	_
92-27	14353-14355	to	_
92-28	14356-14357	a	_
92-29	14358-14363	blank	_
92-30	14364-14365	(	_
92-31	14366-14373	no-task	_
92-32	14374-14375	)	_
92-33	14376-14384	baseline	_
92-34	14385-14386	.	_

93-1	14387-14389	To	_
93-2	14390-14398	estimate	_
93-3	14399-14407	response	_
93-4	14408-14417	amplitude	_
93-5	14418-14419	,	_
93-6	14420-14422	we	_
93-7	14423-14431	measured	_
93-8	14432-14435	the	_
93-9	14436-14444	standard	_
93-10	14445-14454	deviation	_
93-11	14455-14456	(	_
93-12	14457-14459	SD	_
93-13	14460-14461	)	_
93-14	14462-14464	of	_
93-15	14465-14468	the	_
93-16	14469-14476	percent	_
93-17	14477-14481	BOLD	_
93-18	14482-14488	signal	_
93-19	14489-14495	change	_
93-20	14496-14498	of	_
93-21	14499-14502	the	_
93-22	14503-14512	responses	_
93-23	14513-14517	over	_
93-24	14518-14522	time	_
93-25	14523-14524	.	_

94-1	14525-14529	This	_
94-2	14530-14537	measure	_
94-3	14538-14546	provides	_
94-4	14547-14548	a	_
94-5	14549-14554	proxy	_
94-6	14555-14558	for	_
94-7	14559-14562	the	_
94-8	14563-14570	overall	_
94-9	14571-14577	signal	_
94-10	14578-14589	modulations	_
94-11	14590-14597	because	_
94-12	14598-14603	small	_
94-13	14604-14610	signal	_
94-14	14611-14623	fluctuations	_
94-15	14624-14630	should	_
94-16	14631-14638	produce	_
94-17	14639-14644	lower	_
94-18	14645-14647	SD	_
94-19	14648-14651	and	_
94-20	14652-14658	larger	_
94-21	14659-14671	fluctuations	_
94-22	14672-14678	should	_
94-23	14679-14686	produce	_
94-24	14687-14693	higher	_
94-25	14694-14696	SD	_
94-26	14697-14698	.	_

95-1	14699-14702	The	_
95-2	14703-14705	SD	_
95-3	14706-14709	was	_
95-4	14710-14718	assessed	_
95-5	14719-14732	independently	_
95-6	14733-14736	for	_
95-7	14737-14741	each	_
95-8	14742-14745	ROI	_
95-9	14746-14749	and	_
95-10	14750-14754	each	_
95-11	14755-14764	condition	_
95-12	14765-14766	,	_
95-13	14767-14772	first	_
95-14	14773-14779	within	_
95-15	14780-14784	each	_
95-16	14785-14796	participant	_
95-17	14797-14800	and	_
95-18	14801-14805	then	_
95-19	14806-14814	averaged	_
95-20	14815-14821	across	_
95-21	14822-14834	participants	_
95-22	14835-14836	.	_

